Related Experiment Videos
Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs
Matthew G Deneke1, Miguel R Arguedas
1Department of Internal Medicine University Of Alabama at Birmingham, Birmingham, AL 35294, USA.
Expert Review of Vaccines
|January 9, 2004
Summary
Hepatitis A vaccination is safe and effective. This review examines the cost-effectiveness of hepatitis A vaccination programs for both general and high-risk populations, including those with chronic liver disease.
Area of Science:
- Hepatology
- Vaccinology
- Health Economics
Background:
- Hepatitis A vaccines are highly immunogenic and safe.
- Vaccination is recommended for specific groups due to infection risk or severe outcomes.
- Economic evaluations of vaccination programs are crucial for public health policy.
Purpose of the Study:
- To review the available literature on the cost-effectiveness of hepatitis A vaccination programs.
- To analyze economic data for routine and targeted vaccination strategies.
- To assess the value of hepatitis A vaccination in healthy individuals and those with chronic liver disease.
Main Methods:
- Literature review of cost-effectiveness studies on hepatitis A vaccination.
- Analysis of economic data from published studies.
- Synthesis of findings related to different population subgroups.
Main Results:
- Hepatitis A vaccines exhibit strong immunogenicity and an excellent safety profile.
- Vaccination strategies are often cost-effective, particularly in high-risk groups.
- Economic benefits depend on disease incidence, vaccination coverage, and healthcare costs.
Conclusions:
- Hepatitis A vaccination programs are generally cost-effective.
- Targeted vaccination for high-risk populations and individuals with chronic liver disease is often economically favorable.
- Further economic analyses can inform optimal vaccination policies.